The UK Abandoned Biopharma Innovation. Now Biopharma Is Abandoning the UK

And looking at how Eisai talked value around the launch of its subcutaneous Alzheimer’s drug

Sep 15, 2025

Subscribe to Cost Curve Apex to read the rest.

Upgrade to Apex to get access to this post and other subscriber-only content.

No posts found